World Market for Antidepressants is proud to announce the addition of report "World Market for Antidepressants" to their offering.
By: Bharat Book Bureau
May 31, 2008 - PRLog -- In 2004 total world revenues for branded antidepressant drugs was worth over $13bn, but with only ten drugs on the market. However, nine out of these ten drugs faces a loss of patent in the period 2006-2010.  

Table of Contents :

1. Executive Summary
1.1 Aims And Scope of Antidepressants, 2006

2. Introduction
2.1 The Global Cost of Depression
2.2 Overview of the Global Antidepressant Market
2.2 The Threat of Generics

3. Disease Background and Treatment Options
3.1 What Is Depression?
3.2 Different Types Of Depression
3.2.1 Major Depressive Disorder (MDD)
3.2.2 Dysthymia
3.2.3 Bipolar Disorder Is Not Depression
3.2.4 Other Types Of Depression
3.3 Causes Of Depression
3.4 Age, Sex and Depressive Disorders
3.4.1 Depression In Women
3.4.2 Depression In Men
3.4.3 Depression In The Elderly
3.5 The Receptor Hypothesis Of Depression
3.5.1 Serotonin
3.5.2 Norepinephrine (Noradrenaline)
3.5.3 Dopamine
3.5.4 Targets For Drug Development
3.6 Anxiety
3.7 Drug Therapies For Depression
3.7.1 Monoamine Oxidase Inhibitors (Maois)
3.7.2 Tricyclic Antidepressants (TCAs)
3.7.3 Selective Serotonin Re-Uptake Inhibitors
3.7.4 Selective Serotonin and Norepinephrine Re-Uptake Inhibitors
3.7.5 Selective Catecholamine Reuptake Inhibitors
3.8 Leading Drugs In The Antidepressant Market and Their Mode Of Action

4. World Antidepressant Market, 2005-2010
4.1 World Revenue Forecast For Leading Antidepressants
4.2 Market Share by Drug
4.3 Patent Issues and Generic Encroachment
4.4 More Sophisticated Marketing is Required to Drive the Market
4.4.1 Regulatory Restraints Limit Marketing Options
4.4.2 Tapping the Untapped - Can Antidepressant Uptake be Increased by Marketing?
4.4.3 New Indications and Off-Label Use Can Extend an Antidepressant’s Lifetime
4.4.4 Compliance is a Major Concern
4.4.5 New Formulations Will Provide a Small Amount of Protection from Generics
4.4.6 Pricing
4.5 The Psychology of Drug Prescription
4.6 SSRIs Dominate But Will Lose their Majority Market Share by 2010
4.7 SSNRIs Will Increase Their Market Share
4.8 Other Modes of Action Should Hold their Market Share But May Lose Out to New Treatments
4.9 Individual Forecasts For SSRIs
4.9.1 Zoloft (Pfizer)
4.9.2 Paxil/Seroxat (GSk)
4.9.3 Lexapro And Celexa (Lundbeck A/S and Forest Laboratories)
4.9.4 Prozac (Lilly)
4.9.5 Luvox (Astellas Pharma)
4.10 Effexor Is Well-Established But Faces a Challenge from Cymbalta
4.10.1 Effexor (Wyeth)
4.10.2 Cymbalta (Lilly)
4.11 Other Classes of Antidepressants
4.11.1 Wellbutrin (GSK)
4.11.2 Remeron (Azko Nobel)
4.12 The Antidepressant Market Will Become Extremely Dynamic Because of the Next Generation of Therapies

For more information, kindly visit :

Email:Contact Author
Phone:+91 22 27578668
Tags:World, Market, Antidepressants, News, PDF, Format, Market Research, Report
Industry:Medical, Business, Technology
Location:Navi Mumbai - Maharashtra - India
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Bharat Book News
Most Viewed
Daily News

Like PRLog?
Click to Share